摘要
目的探讨早期口服辛伐他汀治疗急性冠脉综合征(ACS)的作用。方法回顾性研究68例不稳定型心绞痛和急性心肌梗死患者,在给予抗血小板、抗凝和抗缺血治疗同时,其中36例接受口服辛伐他汀20mg/d持续治疗至少3个月(辛伐他汀组),另32例未接受辛伐他汀治疗(非辛伐他汀组),随访观察两组患者6个月的心血管事件发生率(死亡、非致命性AMI及复发性心绞痛)。结果辛伐他汀组与非辛伐他汀组比较,6个月终点事件发生率(27.78%、62.50%P<0.05)显著降低。结论ACS患者早期口服辛伐他汀20mg/d能减少心脏缺血事件发生率,用药安全。
Objective To evaluate efficacy of simvatatin treatment in patients with ACS. Methods Sixty eight patients with ACS who received thrombolysis antiplatelet anticoagulant antianginal were divided into two groups: simvastatin group consisted of 36 patients who received simvastatin 20mg / d.The occurrences of death,recurred AMI and angina were assessed during six month. Results The composite endpoint of recurrent cardiac events (27.78%?62.50% P<0.05= in six monthes were lower in the simvastatin group than in the no-simvastatin group. Conclusion Simvastaton decrease the incidence of recurrent ischemic events in patients with ACS.
出处
《中国心血管病研究》
CAS
2005年第5期370-371,共2页
Chinese Journal of Cardiovascular Research
关键词
心绞痛
不稳定型
心肌梗死
辛伐他汀
angina pectoris
unstable
myocardial infarction
Simvaststin
